|
MSI-high
|
0.100 |
Biomarker
|
disease |
BEFREE |
In more specific analyses on MSI-high CRC, regular use of NSAIDs was associated with much stronger risk reduction in the absence of BRAF or KRAS mutations (OR = 0.34, 95% CI = 0.18 to 0.65) but not with KRAS- or BRAF-mutated MSI-high CRC (Pheterogeneity < .001).
|
30388256 |
2019 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Male patients had significantly more gene mutations in N-ras (5.1 vs. 2.3%, OR 2.227, p = 0.012); however, the significance was maintained only for mutations in BRAF (OR 2.104, p = 0.038), MSI-high status (OR 2.003 p = 0.001), and N-ras (OR 3.000, p = 0.010) after the groups were divided by tumor site.
|
29976257 |
2018 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the 24 patients enrolled, four subjects (16.7%) had MSI high tumors: one subject was found to harbor a biallelic PMS2 mutation, one subject had Lynch syndrome (LS) with MSH6 mutation and two subjects had a loss of MLH1/PMS2 proteins/BRAF <sup>wild type</sup>/normal MLH1 sequence.
|
28608265 |
2018 |
|
MSI-high
|
0.100 |
Biomarker
|
disease |
BEFREE |
RET fusions were more frequent in older patients (median age of 66 versus 60 years, P = 0.052), with ECOG PS 1-2 (90% versus 50%, P = 0.02), right-sided (55% versus 32%, P = 0.013), previously unresected primary tumors (58% versus 21%, P < 0.001), RAS and BRAF wild-type (100% versus 40%, P < 0.001) and MSI-high (48% versus 7%, P < 0.001).
|
29538669 |
2018 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Closely recalling the "BRAF history," ALK, ROS1, and NTRK rearrangements more frequently occurred in elderly patients (P = .02) with right-sided tumors (P < .001) and node-spreading (P = .03), RAS wild-type (P < .001), and MSI-high (P < .001) cancers.
|
29370427 |
2017 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MSI-high was associated with better survival, whereas BRAF mutation was associated with worse survival, but these associations did not appreciably differ by age group.
|
26490308 |
2016 |
|
MSI-high
|
0.100 |
Biomarker
|
disease |
BEFREE |
The case presented illustrates that anti-PD-1 therapy can be effectively used to treat CRC patients with MSI-high and BRAF mutant status which is usually considered a poor prognostic category as opposed to MSI-high and BRAF wild type tumors.
|
27355330 |
2016 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The studies were divided into five groups: (1) distribution of KRAS/BRAF mutations in distal and proximal colorectal cancer, the summary OR value was 1.24 versus 4.03, (2) distribution of KRAS/BRAF mutations in CIMP-low/Neg and CIMP-high (CIMP-H) tumors, the summary OR value was 0.77 versus 10.49, (3) distribution of KRAS/BRAF mutations in MSI-low (MSI-L)/microsatellite stable (MSS) and MSI-high (MSI-H) tumors, the summary OR value was 0.51 versus 9.60, (4) proportion of CIMP-H/MSI-H tumors among distal and proximal colorectal tumors, the summary OR value was 3.66 versus 6.54, and (5) proportion of CIMP-H tumors among MSI-L/MSS and MSI-H tumors, the summary OR value was 5.87.
|
28230016 |
2016 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The amount of F. nucleatum was associated with MSI-high (multivariable odd ratio (OR), 5.22; 95% CI 2.86 to 9.55) independent of CIMP and BRAF mutation status, whereas CIMP and BRAF mutation were associated with F. nucleatum only in univariate analyses (p<0.001) but not in multivariate analysis that adjusted for MSI status.
|
26311717 |
2016 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While the increased mutations in BRAF and PTEN in MSI-H CRCs are well accepted, we also support findings of mutations in the mTOR pathway and receptor tyrosine kinase family genes.
|
26517354 |
2015 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations occurred more frequently in females than in males (P=0.02), while the presence of BRAF mutations was significantly associated with the female gender (P=0.006), proximal tumor location (P<0.001), mucinous or poorly differentiated histology (P<0.001), and MSI-high tumors (P<0.001).
|
25632202 |
2015 |
|
MSI-high
|
0.100 |
Biomarker
|
disease |
BEFREE |
For patients with KRAS- and BRAF-mutated CC, but not for double wild-type patients, RFS and OS were significantly better when the tumors were also MSI-H. An interaction test was statistically significant for KRAS and MSI status (P = 0.005), but not for BRAF status (P = 0.14).
|
25361982 |
2015 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study performed MSI analysis on 39 CRC patients selected according to Bethesda guidelines, and BRAF V600E genotyping was performed in 26 cases classified as MSI-high or MSI-low (15 MSI-H and 11 MSI-L).
|
26096739 |
2015 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only 4.3% of patients had MSI-high tumors and there were no MSI-high in tumors with a BRAF mutation.
|
24764675 |
2014 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with the majority subtype of microsatellite stable (MSS)/BRAF-wild-type, MSS/BRAF-mutant, MSI-high/BRAF-mutant, and MSI-high/BRAF-wild-type subtypes showed multivariable colorectal cancer-specific mortality hazard ratios of 1.60 (95% confidence interval [CI] =1.12 to 2.28; P = .009), 0.48 (95% CI = 0.27 to 0.87; P = .02), and 0.25 (95% CI = 0.12 to 0.52; P < .001), respectively.
|
23878352 |
2013 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutation was associated with proximal tumors, mucinous histology, MSI-high (MSI-H), CIMP-high (CIMP-H), and BRAF mutation (P < 0.02).
|
23633456 |
2013 |
|
MSI-high
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cases with KRAS-wild-type/BRAF-wild-type/MSI-high CRC had the most favourable prognosis; those with CRC exhibiting a KRAS- or BRAF-mutation and no MSI had the poorest prognosis.
|
23511557 |
2013 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of CIMP-high, MSI-high and BRAF mutations in cancer increased gradually along colorectum subsites from the rectum to ascending colon.
|
22427238 |
2012 |
|
MSI-high
|
0.100 |
Biomarker
|
disease |
BEFREE |
By assessing combined status of BRAF and MSI, it seemed that BRAF-mutated MSS (microsatellite stable) tumor was an unfavorable subtype, whereas BRAF wild-type MSI-high tumor was a favorable subtype, and BRAF-mutated MSI-high tumor and BRAF wild-type MSS tumor were intermediate subtypes.
|
22147942 |
2012 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated associations between alcohol intake and incident CRC, overall and by microsatellite instability [MSI high (MSI-H) or MSI low/microsatellite stable (MSI-L/MSS)], CpG island methylator phenotype (CIMP positive or CIMP negative), and BRAF mutation (mutated or wild-type) status in the prospective, population-based Iowa Women's Health Study (IWHS; n = 41,836).
|
21900595 |
2011 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The high-methylation epigenotype correlated significantly with MSI-high and BRAF-mutation(+) in concordance with reported CIMP.
|
20028768 |
2010 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of BRAF mutation and MSI-high phenotype were significantly higher in proximal colon cancers.
|
20664940 |
2010 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated associations between smoking and incident colorectal cancer, overall and by microsatellite instability (MSI) phenotype (MSI-high vs MSI-low or microsatellite stable), CpG island methylator phenotype (CIMP positive or CIMP negative), and BRAF mutation status (BRAF mutation positive or BRAF mutation negative), among 37 399 participants in a population-based cohort study (the Iowa Women's Health Study).
|
20587792 |
2010 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a multivariate analysis containing stage, tumor site, nodal status, sex, age, grade, and microsatellite instability (MSI) status, KRAS mutation was associated with grade (P = .0016), while BRAF mutation was significantly associated with female sex (P = .017), and highly significantly associated with right-sided tumors, older age, high grade, and MSI-high tumors (all P < 10(-4)).
|
20008640 |
2010 |
|
MSI-high
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MLH1, MSH2, and BRAF alterations are significantly associated with MSI-H phenotype, unlike APC, APC2 and KRAS alterations.
|
19190129 |
2009 |